<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351893</url>
  </required_header>
  <id_info>
    <org_study_id>17-601-E</org_study_id>
    <nct_id>NCT04351893</nct_id>
  </id_info>
  <brief_title>Craniofacial Microsomia: Accelerating Understanding of the Significance and Etiology</brief_title>
  <acronym>CAUSE</acronym>
  <official_title>Craniofacial Microsomia: Accelerating Understanding of the Significance and Etiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pontificia Universidad Javeriana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Icesi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Nacional Edgardo Rebagliati Martins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigaci√≥n Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica Comfamiliar Risaralda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CAUSE study is a multicenter study, with domestic (n=4) and international (n=6) study&#xD;
      sites. Children and young adults (ages 0-18) who have microtia and/or craniofacial microsomia&#xD;
      and their parents are invited to participate. Children and parents are asked to provide a DNA&#xD;
      sample (blood or saliva) and are asked to upload a few photos of their face. Parents are&#xD;
      asked a short interview. Participants are able to participate from home or at one of four&#xD;
      domestic sites.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify Genetic Variants</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>To identify genetic variants related to the CFM spectrum using whole genome sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize phenotype</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>To characterize the detailed phenotype in individuals with CFM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize markers</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>To characterize ancestry markers in individuals with CFM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coding and non-coding variants</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>To assess coding and non-coding variants in selected candidate genes in individuals with CFM</description>
  </secondary_outcome>
  <enrollment type="Anticipated">883</enrollment>
  <condition>Microtia</condition>
  <condition>Microtia-Anotia</condition>
  <condition>Craniofacial Microsomia</condition>
  <condition>Goldenhar Syndrome</condition>
  <condition>OAVS</condition>
  <condition>OAV Syndrome</condition>
  <condition>Hemifacial Microsomia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants are asked for blood or saliva. If a participant is having a surgery, tissue that&#xD;
      would otherwise be discarded would also be requested.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All CFM cases, their parents, and their relatives regardless of their sex, race, or&#xD;
        ethnicity. The prospective case samples will likely be drawn from outpatient clinics and&#xD;
        medical centers, as well as CFM-related social medial networks.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION:&#xD;
&#xD;
        Cases:&#xD;
&#xD;
          -  Participant with CFM is 0-18 years of age&#xD;
&#xD;
          -  Participant has diagnosis of at least one of the following conditions:&#xD;
&#xD;
               -  Microtia&#xD;
&#xD;
               -  Anotia&#xD;
&#xD;
               -  Facial asymmetry AND preauricular tag(s)&#xD;
&#xD;
               -  Facial asymmetry AND facial tag(s)&#xD;
&#xD;
               -  Facial asymmetry AND epibulbar dermoid&#xD;
&#xD;
               -  Facial asymmetry AND macrostomia (i.e., lateral cleft)&#xD;
&#xD;
               -  Preauricular tag AND epibulbar dermoid&#xD;
&#xD;
               -  Preauricular tag AND macrostomia&#xD;
&#xD;
               -  Facial Tag AND epibulbar dermoid&#xD;
&#xD;
               -  Macrostomia AND epibulbar dermoid&#xD;
&#xD;
          -  Participant's parent or legal guardian has provided written informed consent prior to&#xD;
             enrollment into study (for participants younger than 18 years of age).&#xD;
&#xD;
          -  Participant speaks a language in which they are eligible for consent at their&#xD;
             enrolling site&#xD;
&#xD;
        Parents:&#xD;
&#xD;
          -  Parent participant is the biological parent of a case participant already eligible and&#xD;
             participating in the CAUSE study. Non-genetic parents will be interviewed about their&#xD;
             child's known prenatal and genetic family history but will not be asked to provide DNA&#xD;
             or have facial photographs taken.&#xD;
&#xD;
          -  Participant speaks a language in which they are eligible for consent at their&#xD;
             enrolling site&#xD;
&#xD;
        Other relatives:&#xD;
&#xD;
          -  Other relatives participants, of any age, are related biologically to a case&#xD;
             participant already eligible and participating in the CAUSE study from a multiplex&#xD;
             family (multiple affected individuals with CFM).&#xD;
&#xD;
          -  Participant speaks a language in which they are eligible for consent at their&#xD;
             enrolling site&#xD;
&#xD;
        EXCLUSION:&#xD;
&#xD;
        Cases:&#xD;
&#xD;
          -  Participant is diagnosed with a known syndrome that involves microtia and&#xD;
             underdevelopment of the jaw (Townes-Brocks, Treacher-Collins, Branchiootorenal, Nager,&#xD;
             or Miller syndromes).&#xD;
&#xD;
          -  Participant has abnormal chromosome studies (karyotype).&#xD;
&#xD;
          -  Participant has mandibular asymmetry due to deformational plagiocephaly or&#xD;
             torticollis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Daniela Luquetti, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura P Stueckle, MPH</last_name>
    <phone>206-884-1254</phone>
    <email>laura.stueckle@seattlechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniela Luquetti, MD, PhD</last_name>
    <phone>206-884-5120</phone>
    <email>daniela.luquetti@seattlechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAUSE Study</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Alexis Johns, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAUSE Study</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Amelia Drake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAUSE Study</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Leanne Magee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAUSE</last_name>
      <phone>206-884-1254</phone>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Laura Stueckle, MPH</last_name>
      <phone>206-884-1254</phone>
      <email>laura.stueckle@seattlechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Luquetti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carrie Heike, MS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Javeriana</name>
      <address>
        <city>Bogot√°</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Zaran</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICESI</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Pachajo</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Javeriana</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Hurtad</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cl√≠nica Comfamiliar Risaralda</name>
      <address>
        <city>Pereira</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Liliana Porras Hurtad</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Edgardo Rebagliati Martins</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milagros M. Due√±as Roq</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Gen√©tica M√©dica y Molecular (INGEMM)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Daniel Lapunzina Ba</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Peru</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 11, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Daniela Luquetti</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goldenhar Syndrome</mesh_term>
    <mesh_term>Congenital Microtia</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Investigators do not plan to share, as CFM is a rare disease and could be potentially identifiable.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

